Teva Parkinson's Agent Azilect Will Launch Within 10 Weeks
This article was originally published in The Pink Sheet Daily
Executive Summary
Partner Eisai will continue to co-develop the MAO-B inhibitor for Alzheimer's disease, but it is "still considering" whether it will opt to co-promote the agent for Parkinson's.
You may also be interested in...
FDA Panel To Assess Trial Design As It Reviews Teva's Azilect To Delay Progression Of Parkinson's
Agency reviewers identify numerous issues with analyses and results of ADAGIO trial.
FDA Panel To Assess Trial Design As It Reviews Teva's Azilect To Delay Progression Of Parkinson's
Agency reviewers identify numerous issues with analyses and results of ADAGIO trial.
Advisory Committee To Review Disease Modifying Claim For Teva's Parkinson's Drug
In large early Parkinson's trial, one dose worked but another did not. Review will show how results from innovative trial will be received by FDA.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: